




COUNTRY REPORT By H.Haluk AŞKAROĞLU

IPA- Intraductry Meeting on the participation of Candidate and Potential Candidate Countries in the European Medicines Agency Activities, 1-2 February 2010, London -UK











Pharmacovigilance System

- o Authorized Products on Web (www.kkgm.gov.tr)
- Vaccination Monitoring System established on VIS
- Controls Methods;
 - Routine Control,
 - Up on Complaint
 - o Storages for Veterinary Medicinal Products
 - Manifacture Places
 - Animal Husbandaries
 - Places of Sales





Pharmacovigilance System

- Inspections are carried out by;
 - General Directorate of Protection and Control,
 - Provincial Directorates of MARA,
 - Institute Experts
- Quality Controls of Pharmaceuticals
 - Pendik Veterinary Control and Research Institute
- o Quality Controls of Veterinary biological Products
 - Bornova Veterinary Control and Research Institute



NATIONAL PROCEDURE FOR VETERINARY DOMESTIC PRODUCTION



To grant the Operation Licences to Manufacturing Sites

- The technical and hygienic conditions should meet the requirements
- To grant the Pre-Licences to the products to be manufactured
 - The National Commission For Production Pre-Licences evaluate the dossiers and meet every 3 months for decision.
- To grant The Sales Authorization to the manufactured products,
 - Sampling,
 - Quality Control;
 - Efficacy
 - Safety
 - Sterility





Veterinary Medicinal Products

	Veterinary Biological Products	Veterinary Pharmaceutical Products
Importing Firms	33	44
Imported Authorized Products	413	702
Domestic Manufacturing Firms	11	54
Domestic Authorized Products	108	1522





Alignment with in the EU

- O Not fully alligned with EU legislation
- In Two Years
 - Establishment of Risk Analysis Method for Import and Domestic products,
 - Preparation of Marketing Authorization Directive aligned with EU Legislation
 - Reneweal of all Marketing Authorization dossiers
 - Continious of GMP Legislation preparation,
 - Continious of Full alignment studies.





Challanges

- Lack of GMP authority.
- Weaknesses of market surveillance system,
- Lack of qualified personnel,
- Lack of inspector,
- Insufficient bioequivalance studies for Pharmaceuticals

